{
    "code": "51R00036",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=51R00036",
    "time": "2022-04-08 04:20:02",
    "許可證字號": "衛部藥製字第R00036號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "112\/12\/11",
    "發證\/登錄日期": "107\/12\/11",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHY051R0003602",
    "中文品名": "腦立晰注射劑",
    "英文品名": "NeuraCeq (florbetaben F18 injection)",
    "適應症": "腦立晰注射劑作為腦部正子斷層掃描造影顯影劑，以估計β型澱粉樣蛋白神經炎斑塊(β-amyloid neuritic plaque)的密度，當認知功能障礙的成人患者正在接受阿茲海默氏症(Alzheimer’s Disease)的評估及其他導致認知降低原因的評估時使用。",
    "劑型": "27H注射液劑(無菌製備)",
    "包裝": "外包裝容器：防護鎢罐。包裝容器：3mL、5mL無菌注射針筒",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "新成分",
    "監視期限": "112\/12\/11",
    "主成分略述": "F18-Florbetaben",
    "限制項目": "01國　產 15輸入須附同意書（每批輸入應附原子能委員會核准輸入證明書） 5F免除銜接性試驗",
    "申請商名稱": "6131061700  士宣生技股份有限公司",
    "申請商地址": "新北市新莊區後港一路141號1、2樓及143號1、2樓",
    "主製造廠": [
        {
            "": "TAIWAN",
            "製程": ""
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "7804001510",
            "成分名稱": "F18-Florbetaben",
            "含量描述": "放射活度含量：50-5000 MBq\/mL (1.35-135mCi\/mL)",
            "含量": "0.0000000000",
            "單位": ""
        }
    ],
    "仿單外盒": [
        {
            "title": "01.103-mf18(2.6)腦立晰注射劑仿單-108-10-22.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=51R00036&Seq=002&Type=9"
        },
        {
            "title": "標籤-108-10-22.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=51R00036&Seq=001&Type=8"
        }
    ]
}